Molnupiravir
drugOn this page
Also known as EIDD-1931 ISOPROPYL ESTEREidd-2801MK-4482MolnupiravirPaxlovid
Summary
Molnupiravir (CHEMBL4650320) is an approved small-molecule prodrug (ATC J05AB18); indicated across 7 conditions including severe acute respiratory syndrome and viral infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J05AB18
- Indications: 7 conditions
- Clinical trials: 26
- Chemistry: 329.31 Da · C13H19N3O7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650320 |
| Name | Molnupiravir |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 145996610 |
| ChEBI | CHEBI:180653 |
| ATC | J05AB18 |
| Molecular formula | C13H19N3O7 |
| Molecular weight | 329.31 |
| InChIKey | HTNPEHXGEKVIHG-QCNRFFRDSA-N |
SMILES: CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)NO)O)O
IUPAC name: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate
ChEBI definition: A nucleoside analogue that is N4-hydroxycytidine in which the 5’-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N4-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19.
Pharmacological roles (ChEBI): prodrug, anticoronaviral agent, antiviral drug.
Also known as: EIDD-1931 ISOPROPYL ESTER, Eidd-2801, EIDD-2801, MK-4482, Molnupiravir, MOLNUPIRAVIR, Molnupiravir; Paxlovid
Patent coverage: 1,043 distinct patent families (2,080 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,892 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| viral infectious disease | 3 | MONDO:0005108 | EFO:0000763 |
| influenza | 2 | MONDO:0005812 | EFO:0007328 |
| respiratory syncytial virus infectious disease | 2 | MONDO:0001577 | EFO:1001413 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 26.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE1 | 6 |
| PHASE3 | 5 |
| Not specified | 4 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04381936 | PHASE3 | RECRUITING | Randomised Evaluation of COVID-19 Therapy |
| NCT06667700 | PHASE3 | RECRUITING | A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) |
| NCT04575584 | PHASE2/PHASE3 | TERMINATED | Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) |
| NCT04575597 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) |
| NCT04730206 | PHASE3 | TERMINATED | The DAWN Antivirals Trial for Ambulatory COVID-19 Patients |
| NCT04939428 | PHASE3 | COMPLETED | Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) |
| NCT05459532 | PHASE2/PHASE3 | COMPLETED | A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa |
| NCT05595824 | PHASE3 | COMPLETED | Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19 |
| NCT04746183 | PHASE1/PHASE2 | RECRUITING | AGILE (Early Phase Platform Trial for COVID-19) |
| NCT05041907 | PHASE2 | RECRUITING | Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) |
| NCT05648448 | PHASE2 | RECRUITING | A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza |
| NCT06488300 | PHASE2 | RECRUITING | Assessing Antiviral Treatments in Early Symptomatic RSV |
| NCT06551844 | PHASE2 | RECRUITING | Adaptive Dengue Antiviral Platform Trial |
| NCT04405570 | PHASE2 | COMPLETED | Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 |
| NCT04405739 | PHASE2 | COMPLETED | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) |
| NCT05559905 | PHASE2 | COMPLETED | Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) |
| NCT04392219 | PHASE1 | COMPLETED | COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers |
| NCT05386589 | PHASE1 | COMPLETED | A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) |
| NCT05386758 | PHASE1 | COMPLETED | A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) |
| NCT05818124 | PHASE1 | COMPLETED | Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) |
| NCT06615869 | PHASE1 | COMPLETED | A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) |
| NCT06816030 | PHASE1 | COMPLETED | A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009) |
| NCT05195060 | Not specified | COMPLETED | TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 |
| NCT05412173 | Not specified | COMPLETED | Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers |
| NCT05894603 | Not specified | UNKNOWN | Effectiveness and Safety of New Oral Antivirals for COVID-19 |
| NCT06223932 | Not specified | UNKNOWN | Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).